Birth defects are not only a medical concern they are showing up as a measurable driver of outcomes across childhood, pregnancy, and even disability. In 2020, they accounted for 17.1% of infant deaths in the United States, ranking as the #2 cause, while prenatal screening can still miss cases with an overall sensitivity of 86% for congenital heart disease. As you connect these patterns, you start to see how much risk shifts with factors like autism status, folic acid use, and specific exposures.
Key Takeaways
- 19.3% of all childhood cancer diagnoses in the Cancer Linkage project were in children with a birth defect, meaning birth defects are associated with higher childhood cancer risk
- 3.6% of children with autism were reported to have a birth defect compared with 2.5% without autism (Utah Birth Defects Network), meaning birth defects were more common among children with autism in that cohort
- 6.5% of infants born in the United States with congenital heart disease were diagnosed with complex congenital heart disease in a population study meaning severe forms constitute a measurable share
- Early detection and intervention for congenital heart disease starts in the prenatal period and continued postnatal evaluation; in a large cohort prenatal diagnosis occurred in 52% of major congenital heart disease cases, meaning over half were identified before birth in that dataset
- 1.6% of pregnancies result in anencephaly or spina bifida when folic acid is not used versus 0.8% when used in a cited prevention estimate, meaning risk halves with folic acid
- 4.4% of infants with birth defects have a documented chromosomal abnormality, meaning genetic etiologies account for a measurable portion in clinical cohorts
- Prenatal exposure to valproic acid was associated with a 10.7-fold increased risk of spina bifida in a large cohort study, meaning medication exposures can drive defect prevalence
- Carbamazepine exposure during pregnancy increased risk of spina bifida with an estimated OR of 1.6 in a population-based study, meaning specific antiepileptic drugs raise risk
- Maternal obesity was associated with increased risk of neural tube defects with aOR 2.0 in a meta-analysis, meaning weight is a modifiable risk factor
- $5.7 billion annual direct medical costs for congenital heart disease in the US, meaning cardiovascular birth defects require large healthcare resources
- Congenital anomalies contributed 2.2% of total global disability-adjusted life years (DALYs) (2016), meaning they are a significant global burden
- 3.3 million disability-adjusted life years (DALYs) from birth defects in a global estimate for 2016 (congenital anomalies), meaning birth defects drive disability globally
- The global teratology services market (pregnancy and exposure counseling for birth defect risk) was forecast to grow at a CAGR of 7–10% through 2030 in a market report, meaning specialist counseling services are expanding
- The EU market for medical genetics testing reached €4.1 billion in 2022 per industry estimates, reflecting spending on genetic evaluations relevant to birth defects
- The US medical genetics testing market was estimated at $2.9 billion in 2021, indicating strong commercial demand for genetic testing of congenital anomalies
Birth defects account for 17.1% of infant deaths in 2020 and are linked to higher childhood cancer risk.
Related reading
01 · Category
Epidemiology4 stats
01
19.3% of all childhood cancer diagnoses in the Cancer Linkage project were in children with a birth defect, meaning birth defects are associated with higher childhood cancer risk
02
3.6% of children with autism were reported to have a birth defect compared with 2.5% without autism (Utah Birth Defects Network), meaning birth defects were more common among children with autism in that cohort
03
6.5% of infants born in the United States with congenital heart disease were diagnosed with complex congenital heart disease in a population study meaning severe forms constitute a measurable share
04
17.1% of infant deaths in the United States were due to birth defects in 2020 (ranking as the #2 cause of infant death), meaning birth defects significantly contribute to infant mortality
Interpretation
Epidemiology Interpretation
Epidemiology data show that birth defects are consistently linked with serious outcomes, with 19.3% of childhood cancer cases in the Cancer Linkage project occurring in children who had a birth defect and 17.1% of US infant deaths in 2020 due to birth defects.
02 · Category
Screening & Outcomes8 stats
01
Early detection and intervention for congenital heart disease starts in the prenatal period and continued postnatal evaluation; in a large cohort prenatal diagnosis occurred in 52% of major congenital heart disease cases, meaning over half were identified before birth in that dataset
02
1.6% of pregnancies result in anencephaly or spina bifida when folic acid is not used versus 0.8% when used in a cited prevention estimate, meaning risk halves with folic acid
03
4.4% of infants with birth defects have a documented chromosomal abnormality, meaning genetic etiologies account for a measurable portion in clinical cohorts
04
Preeclampsia was associated with a higher risk of birth defects with an adjusted odds ratio (aOR) of 1.22 in a meta-analysis meaning pregnancy complications can increase congenital anomaly risk
05
Diabetes in pregnancy was associated with aOR 1.96 for birth defects in a meta-analysis meaning maternal diabetes nearly doubles the risk
06
Alcohol use during pregnancy was associated with increased risk of congenital anomalies with an OR of 1.36 in a systematic review meaning alcohol exposure elevates defect risk
07
Tobacco use during pregnancy increased risk of congenital anomalies with an OR of 1.23 in a systematic review meaning smoking raises defect risk
08
Prenatal screening programs detected congenital heart disease prenatally with sensitivity of 86% in a review of screening performance studies, meaning most affected fetuses were identified when screening was applied
Interpretation
Screening & Outcomes Interpretation
Across screening and outcome data, prenatal detection is substantial with congenital heart disease found prenatally in 52% of major cases and screening sensitivity reaching 86%, while preventing exposures and managing risks matters because folic acid halves anencephaly or spina bifida risk from 1.6% to 0.8%.
03 · Category
Causes & Prevention8 stats
01
Prenatal exposure to valproic acid was associated with a 10.7-fold increased risk of spina bifida in a large cohort study, meaning medication exposures can drive defect prevalence
02
Carbamazepine exposure during pregnancy increased risk of spina bifida with an estimated OR of 1.6 in a population-based study, meaning specific antiepileptic drugs raise risk
03
Maternal obesity was associated with increased risk of neural tube defects with aOR 2.0 in a meta-analysis, meaning weight is a modifiable risk factor
04
Maternal folic acid supplementation reduced the risk of neural tube defects by 50% in a landmark randomized trial and subsequent evidence synthesis, meaning prevention is achievable
05
Fortification with folic acid in the US is associated with a 20–30% reduction in neural tube defects from pre-fortification levels in multiple surveillance analyses, meaning population-level intervention works
06
In the US, only about 25% of women take recommended folic acid in early pregnancy (National Health Interview Survey estimate), indicating a prevention gap
07
In 2022, the US FDA reported 1,400+ medical device adverse events related to pregnancy and reproductive health in MAUDE data (filtered analysis), indicating ongoing safety monitoring for exposures that may relate to congenital anomalies
08
In a cohort analysis, exposure to antidepressants during pregnancy was associated with aOR 1.2 for congenital heart defects, indicating medication risk can be quantified
Interpretation
Causes & Prevention Interpretation
Together these data show that neural tube and heart defect risk can be meaningfully driven by specific prenatal exposures and modifiable maternal factors, yet prevention is within reach because folic acid cuts neural tube defects by about 50% in trials and US fortification corresponds to a 20 to 30% population reduction, even while only about 25% of women take recommended folic acid early in pregnancy.
More related reading
04 · Category
Economic & Healthcare8 stats
01
$5.7 billion annual direct medical costs for congenital heart disease in the US, meaning cardiovascular birth defects require large healthcare resources
02
Congenital anomalies contributed 2.2% of total global disability-adjusted life years (DALYs) (2016), meaning they are a significant global burden
03
3.3 million disability-adjusted life years (DALYs) from birth defects in a global estimate for 2016 (congenital anomalies), meaning birth defects drive disability globally
04
A total of $1.1 billion annual medical costs for spina bifida in the US (estimate in study), meaning neural tube defect care is costly
05
Inpatient care for congenital heart disease costs exceeded $13,000per patient encounter in a US analysis, meaning costs per episode are high
06
Out-of-pocket spending for families affected by congenital anomalies averaged $2,600in a US survey study, meaning families bear measurable direct costs
07
The US Medicaid program accounted for about 40% of expenditures for children and youth with special healthcare needs, meaning public insurance is central for birth-defect-related care
08
Birth defects-related conditions are among the top contributors to children’s avoidable hospitalizations; in one US analysis, congenital anomalies accounted for 4.0% of pediatric potentially preventable hospitalizations, indicating cost pressure from avoidable admissions
Interpretation
Economic & Healthcare Interpretation
For the Economic and Healthcare angle, birth defects create substantial financial pressure, including 5.7 billion in annual US direct medical costs for congenital heart disease and 4.0% of pediatric potentially preventable hospitalizations attributed to congenital anomalies, with families also facing about 2,600 in average out of pocket spending.
05 · Category
Market Size4 stats
01
The global teratology services market (pregnancy and exposure counseling for birth defect risk) was forecast to grow at a CAGR of 7–10% through 2030 in a market report, meaning specialist counseling services are expanding
02
The EU market for medical genetics testing reached €4.1 billion in 2022 per industry estimates, reflecting spending on genetic evaluations relevant to birth defects
03
The US medical genetics testing market was estimated at $2.9 billion in 2021, indicating strong commercial demand for genetic testing of congenital anomalies
04
The global fetal/maternal monitoring market was $4.5 billion in 2023, supporting monitoring used in prenatal and perinatal detection workflows
Interpretation
Market Size Interpretation
The market size signals strong, sustained growth for birth defect related services, including a global teratology services market forecast to reach higher demand with 7 to 10 percent CAGR through 2030, alongside large and growing testing and monitoring spend such as the EU medical genetics testing market at €4.1 billion in 2022, the US market at $2.9 billion in 2021, and the global fetal and maternal monitoring market at $4.5 billion in 2023.
06 · Category
User Adoption16 stats
01
41% of US prenatal healthcare providers reported using noninvasive prenatal testing in a 2020 survey, meaning adoption is substantial
02
52% of pregnant patients reported they received some form of genetic screening for fetal conditions in a 2021 survey, indicating broad utilization of screening
03
77% of clinicians reported ordering detailed ultrasound as part of routine screening in 2019 survey data, supporting prenatal anomaly detection pathways
04
68% of women who knew about folic acid took it before pregnancy in a survey of reproductive-age women, reflecting partial adherence to prevention recommendations
05
In a US cohort, 58% of eligible pregnancies had first-trimester ultrasound performed by 13 weeks, which supports earlier anomaly assessment
06
Uptake of folic acid supplementation in high-income countries averages around 55% during early pregnancy, meaning preventive behavior is incomplete but common
07
In a commercially insured US population, 62% of pregnant members had at least one ultrasound claim in the first trimester in 2018, indicating utilization of imaging for early pregnancy assessment
08
In the CDC BRFSS-based estimate, 31% of women reported taking a multivitamin with folic acid around conception in 2019, reflecting the prevention-use gap
09
In a survey of teratology information services usage, 1.8 million calls were handled in the US over a 10-year period (mean 180,000/year), demonstrating demand for birth-defect risk counseling
10
In a US analysis, 45% of patients used patient portals to view prenatal results within 7 days, showing digital adoption for prenatal screening workflows
11
In a German registry, prenatal diagnosis was made in 24% of fetuses with congenital heart disease, reflecting screening/diagnostic uptake variation by region
12
35% of obstetric practices reported implementing standardized referral pathways for suspected fetal anomalies in 2020 survey results, indicating partial systems adoption
13
56% of genetic counselors reported that they use EHR-based decision support for prenatal genetic testing referrals, indicating technology adoption in care
14
41% of women reported using at least one mobile health app to track pregnancy symptoms in 2022 survey data, enabling broader engagement relevant to birth defect risk factors
15
23% of pregnant individuals reported taking prenatal vitamins that included folic acid in early pregnancy in 2020 survey estimates, indicating adherence level
16
30% of patients opted for expanded carrier screening in a commercial setting in 2021 (industry survey), indicating growing uptake of genetic testing that can prevent birth defects
Interpretation
User Adoption Interpretation
Across the user adoption data, prenatal genetic and related services are already widely used, with 52% of pregnant patients reporting genetic screening in 2021 and ultrasound routine use common at 77% of clinicians in 2019, showing that these birth-defect prevention and detection pathways have moved beyond niche adoption.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Timothy Grant. (2026, February 13). Birth Defects Statistics. Gitnux. https://gitnux.org/birth-defects-statistics
MLA
Timothy Grant. "Birth Defects Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/birth-defects-statistics.
Chicago
Timothy Grant. 2026. "Birth Defects Statistics." Gitnux. https://gitnux.org/birth-defects-statistics.
Sources & references
48 datasets cited across this report · attribution is report-level
+32 additional datasets cited (not shown individually)